Claims Scope:

Patent issued April 11, 2023. 

 

90% Sequence Identity – Compositions & Method-like claims 

 

Systems and “compositions for use in treating cancer” comprising helper and envelope plasmids, and a therapeutic plasmid having either shRNA or microRNA directed against SEQ ID NO 59 (FDPS targets sequence #4), comprising shRNA SEQ 4, or microRNA SEQ 5-6. 

 

Includes combination claims with aminobisphosphonates 

 

Notably shRNA SEQ 1-3 not allowed, nor microRNA 7-10.